A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use, needs to be studied. IL-17 inhibitors increase...

Full description

Bibliographic Details
Main Authors: Vishnu Eshwar, Ashwin Kamath, Rajeshwari Shastry, Ashok K. Shenoy, Priyanka Kamath
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Pharmaceuticals
Subjects:
secukinumab
interleukin 17
adverse event
psoriasis
inflammatory bowel disease
Online Access:https://www.mdpi.com/1424-8247/15/11/1365

Internet

https://www.mdpi.com/1424-8247/15/11/1365

Similar Items